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Abstract
In this paper, I will explore the development of vaginal microbicides (female-initiated HIV prevention 
methods designed as gels, fi lms, sponges and rings women can insert vaginally before having sex to 
protect themselves against HIV infection) as a women’s health intervention that entangles feminist 
ideals of empowerment with biomedical enterprise. The fi eld of vaginal microbicide development pays 
heed to both the specifi c biological vulnerabilities of ‘the female body’ that are understood to make 
women more susceptible to HIV infection as well as the social gendered power relations that leave 
women at a higher risk of HIV within the power dynamics of their sexual relationships. I am particularly 
interested in the ambiguity that emerges between the eff ects of a biomedical search for facticity 
through clinical trial testing and advocacy promises of empowerment, which I will explore through 
analysing the clinical trials of Nonoxynol-9 microbicide candidates in the early 1990s – a microbicide 
candidate that was continuously linked to vaginal ulceration and consequently a potential increase in 
receptivity to HIV. Through an interrogation of clinical trial reports, advocacy documents and a social 
science study in which the women trial participants articulated Nonoxynol-9 as their “protector”, I 
argue that the story of Nonoxynol-9 shows an intrinsic ambiguity between the fi eld’s feminist promise 
of empowerment and the eff ects of the biomedical search for an eff ective microbicide candidate. 
Drawing on the work of Karen Barad, I argue that agential realism is able to provide a robust analytical 
framework to interrogate the political and ethical eff ects of this ambiguity that the fi eld’s own discourse 
of empowerment does not suffi  ciently provide.
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Introduction
In this paper, I explore a women’s health interven-
tion that entangles feminist ideals with biomedical 
enterprise – the development of vaginal microbi-
cides (female-initiated HIV prevention methods 
designed as gels, fi lms, sponges and rings women 
can insert vaginally before having sex to protect 
themselves against HIV infection). In particular, I 
am interested in the relations and discrepancies 
between feminist ideals of women’s empower-
ment and the eff ects of biomedical process that 
become apparent through clinical trial testing of 
microbicide candidates. At present, microbicides 
are being tested in clinical trials and have been 
since the early 1990s with mixed and at times 
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controversial results. Since the early 1990s eight 
microbicide candidates have made it to trial: Non-
oxynol-9, SAVVY, Cellulose Sulphate, Carraguard, 
PRO 2000, Buff ergel and Tenofovir gel. Currently, 
the new candidate with the most promise is the 
vaginal ring, which proved safe and eff ective in 
recent clinical trials and is currently undergoing 
open-label studies (Baeten 2016: 2; MTN, 2016). 
The advocacy campaign for microbicides has 
been voiced as an explicitly feminist campaign, 
largely fuelled by an understanding of gender 
dynamics that speaks in terms of women’s 
empowerment and aims to transform gender and 
sexual power relations. According to the Global 
Campaign for Microbicides (GCM), the largest 
microbicide global advocacy body, the microbi-
cide would off er women a way to empower them-
selves in the context of their sexual lives, where 
other forms of protection, such as a condom, may 
not be available to them or may be problematic. 
The field of vaginal microbicide development 
pays heed to both the specifi c biological vulnera-
bilities of ‘the female body’ that are understood to 
make women more susceptible to HIV infection as 
well as the gendered relations that leave women 
at a higher risk of HIV within the power dynamics 
of their sexual relationships. The development of 
microbicide’s engagement with the female body, 
gender dynamics, ideals of empowerment and the 
HIV virus places the fi eld at a fascinating juncture, 
at the intersections of nature and culture, sex and 
gender, material real and utopic future – junctures 
that correspond with the aims of many STS 
approaches, including the work of ‘feminist new 
materialisms’. 
In this paper, I engage Karen Barad’s (1998, 
2003, 2007) performative onto-epistemology 
of agential realism and provide a reading of the 
development of microbicides which foregrounds 
the clinical trial as an apparatus of bodily produc-
tion, i.e. a socio-scientifi c milieu constitutive of 
the bodies put on trial. I understand Barad’s theo-
retical work to resonate with the aims of microbi-
cide development as Barad both engages science 
and technology while paying attention to the 
sexual politics of scientifi c development. As such, 
Barad’s work is situated on the cusp of STS and 
its predominant focus on the scientifi c produc-
tion of human/nonhuman hybridity, and feminist 
and queer theory that foregrounds the performa-
tivity of sex(uality) and gender (Barad, 1998, 2012, 
2015). As such, Barad not only celebrates human-
nonhuman hybridization, but also pays heed to 
the processes through which the human comes 
into being and the potential dehumanisation 
such constructions might entail – “the more or less 
“human”, the inhuman, the humanly unthinkable” 
(Butler, 1993: 8). Consequently, agential realism 
is not only a fruitful method for a critical analysis 
of science and technology, but also a theoretical 
engagement that lends itself to political aims of 
embodied resistance to gendered and sexual-
ised power structures. Such a theoretical focus 
resonates with the key issue at stake in this paper 
– the materialisation of empowerment ideals. 
In this paper, I will look at the fi rst microbicide 
candidate that made it to trial, which is also the 
most controversial to date, Nonoxynol-9. I will 
analyse the Nonoxynol-9 trials as a case study 
that very clearly epitomises the discrepancy 
between the eff ects of a biomedical search for 
facticity through clinical trial testing and advocacy 
promises of empowerment. However, this case 
study is not intended to represent the entirety of 
the fi eld of microbicides and several decades of 
candidate testing. 
The argument set out in this paper is situated 
in a more encompassing textual research project 
based on a collected archive of the development 
of microbicides from the early 1990s until the 
end of the GCM in 2012 (see Van der Zaag, forth-
coming). This archive consists of a collection of 
advocacy documents, clinical trial reports and 
social science studies predominantly collected 
through keyword searches in the PubMed 
database and the GCM website. This collection of 
texts allows me to investigate the diff erent articu-
lations of the development of Nonoxynol-9 and 
the manner in which diff erent aims, ideals and 
materialities were put into discourse. 
It is no coincidence that I place clinical trial 
reports together with social science studies 
and advocacy documents. I aim to show the 
complexity of the fi eld of vaginal microbicides, the 
diff erent meanings and materialisations that have 
been construed by the wide variety of actors that 
comprise this fi eld – both human and nonhuman. 
As such, I engage in a mode of critique that shows 
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the frictions and relations between multiple actors 
in their aim to develop a technology to protect 
women against HIV infection while furthering 
ideals of women’s empowerment. Indeed, I 
am focused on the diff erences and similarities 
between women’s health advocacy documents, 
biomedical clinical trial reports and social science 
studies to show the diff erences in how the micro-
bicide is articulated to intervene into women’s 
bodies and socio-sexual lives, paying particular 
attention to the gendered vocabularies utilised. 
My approach to these articulations insists that 
they do not merely represent the problematic 
the fi eld engages in. Rather, the multiple articu-
lations that make up this fi eld are constructive, 
they constitute what is at stake within the fi eld 
of microbicide development, the microbicide as 
a technology and the women implicated in its 
intervention. I question, what happens to feminist 
ideals of empowerment when they materialise 
through biomedical process?
Women’s empowerment as 
a vehicle of inclusion 
According to UNAIDS statistics, worldwide there 
are around 37 million people living with HIV 
(UNAIDS, 2016: 1), of which women and girls make 
up more than half (UNAIDS, 2016: 8). Globally, 
the number of women living with HIV has been 
on the rise since the early 1990s. This increase is 
shown to be more prominent in some parts of the 
world than others, such as in Sub-Saharan Africa 
(UNAIDS, 2016: 8). Moreover, the UNAIDS 2010 
report states that in Sub-Saharan Africa young 
women are eight times more likely to be HIV posi-
tive than men their age (UNAIDS, 2010: 10). This 
increasing feminisation of the HIV epidemic con-
stitutes the need for and has been the backdrop 
to the development of vaginal microbicides. 
The development of microbicides commenced 
in the early 1990s when women were only just 
becoming visible as a group at risk of HIV. During 
this time, the concept of ‘empowerment’ func-
tioned as a vehicle for women’s inclusion into 
global HIV prevention discourse (WHO, 1990, 
1992, 1993, 1994, 1995). Within global health 
discourse women at risk of HIV were articulated 
as subject to a lack of power in their gendered 
lives and this distribution of power was under-
stood to fuel their vulnerability to HIV infection. 
Subsequently, ‘empowerment’ was understood 
as alleviating this particular vulnerability, brought 
about either through behavioural change or 
biomedical intervention. However, although the 
need for female initiated HIV prevention was 
recognised in early 1990s global health discourse, 
most attention was given to women’s socio-
economic empowerment initiatives and condom 
logistics. This is the point where the develop-
ment of vaginal microbicides critically set its own 
direction, as it took up biomedicine as a way to 
transform women’s vulnerability to HIV infection 
and expand an understanding of women’s 
empowerment towards biomedical intervention 
into the female body. 
From its initial conceptualisation, the vaginal 
microbicide has been understood as an explicitly 
sexual technology potentially transformative of 
both gender dynamics and HIV susceptibility, as 
the epidemiologist Zena Stein argued in 1990:
At present, the sole physical barrier promoted for 
the prevention of sexual transmission of human 
immunodefi ciency virus (HIV) infection from men 
to women is the condom. With condoms, active 
male cooperation is crucial. The proposition of this 
paper is that the empowerment of women is crucial 
for the HIV transmission to women. It follows that 
prophylaxis must include procedures that rely on 
the woman and are under her control (Stein, 1990: 
460).
Stein put female controlled prophylaxes forward 
as devices that might very well be less effi  cacious 
than a condom, but more eff ective as they are tai-
lored to meet women’s specifi c needs. As female-
controlled prophylaxes were aimed at protecting 
women’s bodies against HIV and simultaneously 
further women’s empowerment, Stein articulated 
an intimate relation between social dimensions of 
power and scientifi c interventions into the female 
body. The promise of vaginal microbicides entan-
gles the biological susceptibility to the HIV virus 
with the transformation of socio-sexual power 
relations. As Catherine Montgomery writes, “[t]he 
fusing of women’s biological vulnerability to HIV 
with their social vulnerability to infection seam-
lessly led to the medicalisation of powerlessness 
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and the search for a medical solution to it” (Mont-
gomery, 2012: 928).
The idea of a vaginal microbicide as a female-
initiated HIV prevention method was soon taken 
up by Lori Heise (Elias and Heise, 1994), the former 
director of the GCM. The GCM remained the prime 
advocacy body in microbicide development 
before it disbanded in 2012. This campaign was 
officially launched at the twelfth AIDS Confer-
ence in Geneva in 1998 (GCM, 2009a). Although 
the GCM’s headquarters were based in the U.S., 
they described themselves as a – “broad-based, 
international coalition of organisations working to 
accelerate access to new HIV prevention options” 
(GCM, 2012a). Their main goal was “to focus world 
attention on the critical need for new HIV preven-
tion options, especially for women” (GCM, 2007a, 
2010c). The Campaign represented women’s need 
for a microbicide, how a microbicide will intervene 
in women’s lives and, importantly, how the micro-
bicide will function as an empowering tech-
nology. What is signifi cant of the GCM is that they 
both engaged with an understanding of women’s 
vulnerability to HIV as a social problematic as well 
as the specifi c vulnerability of the female body, 
thereby simultaneously engaging the social and 
the biological without reinstating a sex/gender, 
nature/culture dichotomy. This entanglement 
of physical and social aspects of HIV infection 
becomes visible in their articulation of women’s 
risk, an articulation of vulnerability that is consist-
ently repeated throughout their campaign 
discourse. They claim that the biological factors 
that contribute to women’s risk of HIV consists of 
the following:
Biological factors contributing to women’s risk of 
HIV:
-Women are more likely than men to contract HIV 
at a single exposure.
-The cervix is a site of particular vulnerability.
-Younger women are at even greater risk, since the 
cervix is physiologically less mature and therefore 
more vulnerable to infection.
-Women with asymptomatic STIs may not 
seek treatment, which can result in serious 
long-term consequences such as infertility, pelvic 
infl ammatory disease, ectopic pregnancy, infant 
mortality, and cervical cancer.
Social and economic inequities also contribute to 
women’s risk:
-The vast majority of women with HIV were infected 
during heterosexual sex – many by their husbands 
or boyfriends.
-Women may infl uence but do not control the 
sexual and/or drug-using behaviour of their male 
partners.
-Violence, coercion, and economic dependency 
in many women’s relationships make it diffi  cult to 
“negotiate” condom use or to leave a partnership 
that puts them at risk.
-In many societies, women and girls are 
discouraged from learning about their bodies and 
about sex in general.
-Often, women are socialised to leave sexual 
decision-making to men.
-Gender-based social norms often encourage men 
to seek multiple partners, while women bare the 
shame and stigma of disease.
-Growing economic inequality and eroding social 
support have driven many women into commercial 
sex work to support their families (GCM, 2009b).
For the GCM, a vaginal microbicide promises to 
provide women with a HIV prevention method 
that would protect their bodies against HIV which 
women would be able to incorporate into their 
socio-sexual lives. The specific aim of the GCM 
was to provide women with a tool they could 
control and that would answer to women’s diff er-
ent needs. Importantly, the GCM worked in close 
collaboration with biomedical eff orts of microbi-
cide development and its large-scale roll out of 
trials, to ensure that the trials themselves would 
be spaces of empowerment and that women’s 
vulnerability would not be increased through bio-
medical process (GCM, 2007b). However, I argue, 
it is in this meeting of feminist ideals and politics 
and biomedical enterprise where problems arise, 
particularly in terms of women’s vulnerability to 
HIV infection within clinical trials.
The clinical trials
Women’s vulnerability to HIV, physically, socially, 
sexually and economically, is a key controversy 
within the microbicide Randomised Controlled 
Trials (RCTs) and the fi eld of microbicide develop-
ment is very much aware of these complexities. 
To address these, a symposium was organised in 
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1997 in Washington D.C. which highlighted key 
concerns and ethical deliberations that are still in 
eff ect in the fi eld. This symposium was convened 
by WHAM (Women’s Health Advocates on Micro-
bicides, the main advocacy body preceding the 
GCM) and the Population Council (the initial bio-
medical collaborator in the microbicide fi eld), to 
discuss ethical and practical dilemmas of micro-
bicide testing. It brought together 55 experts in 
clinical, biological and social science and activists, 
biomedical ethicists from 15 countries in Africa, 
Asia, Latin America, Europe, and the U.S. The sym-
posium took place when the concept of a topical 
microbicide was just taking shape, when bounda-
ries between science and women’s health activ-
ism were starting to become less rigid and the 
fi rst Nonoxynol-9 based candidates were entering 
human clinical trials. Importantly, as the below 
excerpt of the symposium report indicates, the 
symposium situated the clinical trial as embedded 
and active in power dynamics. 
Although women need and deserve a technology 
they control, microbicide research should not be 
allowed to defl ect attention from the underlying 
power inequities that put women at risk. 
Microbicide research must be seen as part of an 
overall program of STI/HIV prevention that includes 
eff orts to empower women and to improve the 
detection and management of STIs among women, 
especially in resource poor settings. (Heise et al., 
1998: VII).
What the clinical trial was understood to do, 
entailed more than testing for mere efficacy. 
Rather the effi  cacy of the microbicide candidate 
became intimately related with power dynam-
ics. This is a manner of understanding biomedi-
cal engagement that remained with the GCM 
throughout its later advocacy efforts (GCM, 
2010a). However, through the manner in which 
power is understood and the authority ascribed to 
biomedical knowledge seeking practices, the clin-
ical testing of microbicides is almost instantly sep-
arated from these more encompassing relations 
and power dynamics. This has remained intrinsic 
to, and one of the key complexities in, the devel-
opment of vaginal microbicides. Although the 
clinical trial is put forward as an active component 
in women’s gendered power dynamics and pro-
tection against the HIV virus, it is simultaneously 
understood as ‘the gold standard’ of microbicide 
testing (Heise et al., 1998: 10; see also Rosengarten 
and Michael, 2013).
The RCT as the gold standard for microbicide 
testing is directly related to the demands of regu-
latory institutions (the United States Food and 
Drug Administration being the most prominent) 
by which the candidate needs to be approved 
before it can be produced for large scale distri-
bution, should the candidate prove effi  cacious. 
Although the FDA does not explicitly articulate 
the RCT as the gold standard for the testing of new 
drugs, their guidelines are interpreted as such that 
the fi eld endeavours to answer to their require-
ments through the RCT (AVAC, 2015; GCM, 2015; 
FDA, 2015; see also Will, 2007). The manner in 
which this tension between the RCT as an empow-
ering space and the RCT as the gold standard of 
microbicide testing plays out is through women’s 
(vulnerability to) HIV infection. On the one hand 
every eff ort is taken to decrease HIV infections 
within the clinical trial, specifi cally by providing 
STI testing, promoting the use of condoms and 
providing safe sex counselling. However, the 
manner in which data is sourced means that, 
despite the trial’s preventative measures, women’s 
HIV infection is anticipated.
The effi  cacy clinical trials are only conducted 
on HIV negative women. The data of these trials 
is readable through women’s seroconversions (to 
HIV infections) as the number of HIV infections in 
the placebo arm shows how effi  cacious the micro-
bicide candidate in the product arm is. “The higher 
the incidence of HIV in the host community, the 
smaller the number of participants necessary to 
detect a diff erence between a microbicide and 
a placebo. As incidence declines, the number of 
women necessary to detect an eff ect rises rapidly, 
making trials among low-incidence populations 
extremely cumbersome and expensive” (Heise et 
al., 1998: 18). The RCTs need to be conducted on 
populations with a high prevalence of HIV infec-
tions in order to gather enough data for statisti-
cally signifi cant analysis, which for the phase III 
trials (human trials testing effi  cacy) would mean 
a multi-site population. If the data is not statisti-
cally signifi cant the measured effi  cacy of a micro-
bicide candidate could have been due to chance. 
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In other words, statistical signifi cance provides 
‘objective’ data concerning the effect of the 
microbicide candidate on the HIV virus within the 
female body. Statistical signifi cance remains the 
core method for the success of a clinical trial in 
biomedical terms, as its success is understood as 
providing proof of the effi  cacy of the microbicide 
candidate, which is called ‘proof of concept’. 
Because of the need for statistical signifi cance 
to show the effi  cacy of the microbicide candidate, 
the population the microbicide is tested on is 
selected according to HIV incidence (the number 
of HIV infections across the potential trial popu-
lation) and women’s specifi c risk of HIV infection 
within their sexual relations (as opposed to for 
instance drug injection). These criteria are aimed 
at ensuring that the trialists know whether sero-
conversions occurred during vaginal sex and 
therefore, consequently, the measure of protec-
tion is due to the efficacy of the microbicide. 
This need of HIV infection leads trialists to enrol 
groups of women into the RCT who are highly 
vulnerable to HIV infection in specifi c ways. In 
particular, female sex workers and women who 
have diffi  culty negotiating condom use. In other 
words, precisely those women who are under-
stood to be in need of a microbicide, because of 
what advocates indicate as, their socio-sexual 
vulnerability, are desirable participants of the 
RCT because their specifi c vulnerability will make 
the RCT more likely to produce a statistically 
signifi cant result. “This reality helps ensure that 
despite the best eff orts of trial sponsors to actively 
promote condom use in both trial groups, there 
will be some women who are unable to do so 
(making it easier to evaluate a potential microbi-
cide)” (Heise et al., 1998: IX).
Although biomedical development is inherent 
to the advocacy promise of empowerment, the 
manner in which women’s vulnerability to HIV 
infection is anticipated in light of the trial’s success 
is not easily reconcilable with the advocacy eff orts 
to diminish this vulnerability through central-
ising women’s needs, protection and empower-
ment. There is a clear discrepancy between the 
advocacy promise of women’s empowerment and 
the biomedical development of microbicides that 
hinges on women’s HIV infections within the trial. 
However, although ideals and materialities stand 
in ambiguous relation, they are not mutually 
exclusive. Thus, in order to explicate what is at 
stake in the development of microbicides, I concur 
with Jungar and Oinas’ statement that “[a]nalyses 
of potentially helpful interventions into the 
epidemic as a discursive-material reality become 
crucial” (Jungar and Oinas, 2010: 179). Textual 
analysis of the development of microbicides 
allows me to bring biomedical articulations of the 
female body, microbicide candidates and virus, 
social science articulations of women’s experience 
and advocacy ideals of women’s empowerment 
within the same performative frame. In doing so, 
I am interested in how diff erences, such as the 
aforementioned ambiguity, are negotiated and 
how such negotiations come to bear on the micro-
bicides potential user and thus the empowerment 
a microbicide is able to promise. As such, my work 
resonates with Nelly Oudshoorn’s research into 
clinical trials where “…the development phase of 
a technology becomes an intriguing location for 
understanding the co-construction of users and 
technologies” (Oudshoorn, 2003a: 213; see also 
Oudshoorn, 2003b).
Furthermore, this study makes a significant 
contribution to social science in HIV and in 
particular social science studies of the develop-
ment of vaginal microbicides which engage the 
experiences of trial participants (for instance the 
work of Saethre and Stadler, 2010, 2011), but often 
leave the workings of a trial unexamined (Will, 
2007: 85) and present their fi ndings as representa-
tive of women’s experience. In critical contrast, 
and aided by my textual point of entry into the 
microbicide fi eld, I do not claim direct access to 
women trial participants’ experience. Although 
my own work is in conversation with these studies, 
what I am interested in is the ways in which these 
experiences and voices come to be articulated 
through social science and as such become part 
of the apparatus of bodily production of micro-
bicide development. Such a performative scope 
is in line with an emerging body of HIV research 
that explicitly foregrounds the materialities of HIV, 
bodies and prevention technologies and biomedi-
cine’s constitutive role herein (see for instance 
Rosengarten, 2009; Race, 2009; Montgomery, 
2012; McKnight and Van der Zaag, 2015). That 
is to say, I am interested in how bodies come to 
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matter in microbicide development as a material-
discursive performative process that includes the 
articulations of materiality, experiences and ideals. 
Agential realism
Karen Barad’s work is embedded within so-called 
feminist new materialism, currently gaining rapid 
momentum within feminist theory. In correspond-
ence with STS agendas, these new materialisms 
are concerned with the breakdown of the dichot-
omous oppositions between biology and society, 
nature and culture, human and nonhuman and 
are characterised by paying signifi cant attention 
to nonhuman actors, especially within the scien-
tifi cally focused strands of this multifarious body 
of work. Here, a wide array of theoretical interven-
tions and trajectories is encompassed, including 
engagements with matter’s literacy (Kirby, 1997, 
2011), engagements with sexual difference and 
its futurity (Grosz, 2005, 2011; Braidotti, 2011a), the 
constitutive role of the sciences (Haraway, 1997; 
Barad, 2007) and more ecological investigations 
(Haraway, 2016; Alaimo, 2010). Many feminist new 
materialisms, including the work of Barad, are 
pitched against the so-called cultural turn and its 
focus on cultural processes of signification and 
identity in the theorisation of sex(uality) (Hem-
mings, 2011). In particular, Judith Butler’s notion 
of materiality is often invoked as failing to engage 
with the materiality of the body (Cheah, 1996; 
Kerin, 1999; Kirby, 1999, 2011; Fraser, 2002; Barad, 
1998, 2003, 2007). 
What is at stake here are the various materiali-
ties these theories engage with and thus the multi-
plicity of materiality that ensues. Sari Irni (2013) 
has coined this ‘the politics of materiality’ which 
constitutes a certain disciplinary hierarchy of value 
where engagements with the natural sciences (or 
‘capital S science’ (Willy, 2016: 4)) are understood 
to be the primary site where materiality is to be 
found1. Attention to such politics of materiality is 
often articulated through the conceptualisation 
of this relatively nascent fi eld of theory. Should 
we speak of new materialisms (Coole and Frost, 
2010), material feminisms (Alaimo and Hekman, 
2008), neo-materialism (Braidotti, 2000)? These 
questions are not so much attempts to canonise 
the fi eld, as they are questions of politics phrased 
through scholarly genealogical trajectories. Here, 
it is important to state that these materialisms are 
not necessarily new, but rather are enabled by a 
wide range of past feminist theories on materi-
ality including Simone de Beauvoir’s (1997[1949]) 
engagement with biology, Shulamith Firestone’s 
(1970) feminist revolution through technology, 
Emily Martin’s (1989) discourse analysis of the 
reproductive system, Sandra Harding (1986, 1991) 
postcolonial critique of science and of course, 
Donna Haraway’s (1976, 1978) critique of the 
distinction between nature and culture. In other 
words, and to speak with Sara Ahmed (2008), 
new materialisms can often be seen to enact 
a ‘founding gesture’ - a certain neglect of past 
feminist theory on materiality, articulated through 
a ‘return to matter’ (Hemmings, 2011), that comes 
to substantiate the ‘new’ of this multifarious body 
of work. However, such a gesture has direct meth-
odological and political implications problematic 
for new materialism as a feminist project. Barad 
has a complex position within these feminist 
critiques. On the one hand, she repeats the same 
founding gesture by setting her theory up against 
Butler’s performative notion of materiality and 
thus enacting a ‘return to matter’. On the other 
hand, her agential realism explicitly allows for 
theorisations of sex(uality) and dehumanisation, 
even if Barad rarely engages such materialities 
herself.
Karen Barad’s approach (1998, 2003, 2007, 2012, 
2015) is both deeply embedded in Haraway’s 
socialist feminist theory (historical materialism) 
as well as Judith Butler’s performative materialism 
(even if in critical relation). Such embeddedness 
makes clear that Barad’s agential realism is indeed 
materialist, but not necessarily new. Furthermore, 
the multifarious genealogy of Barad’s agential 
realism, already illuminates that she engages, or 
at least opens up a theoretical space to engage, 
a multiplicity of materiality. What I am particu-
larly interested in is Barad’s interest in non/human 
hybridization and science, while a methodological 
and political emphasis on lived reality (Haraway) 
and the performativity of sex/gender and (de)
humanisation (Butler) remain at stake. Therefore, I 
utilise Barad’s agential realism, not because of the 
specifi c science (quantum physics) she engages. 
Rather, I am interested in the manner in which 
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Barad engages science as a fi eld of operations 
through which bodies come to matter. Thus, I 
would coin Barad’s approach, as well as my own, 
neomaterialist in an eff ort to both articulate its 
trajectory through historical and performative 
materialisms, while paying heed to the contempo-
raneity of the current feminist materialist debates.
Karen Barad takes Judith Butler’s notion of 
materiality and performativity (Butler, 1993) and 
its concern with processes of (de)humanisation 
and rearticulates this theory to account for scien-
tifi c practice. Karen Barad’s point of departure 
(1998, 2003, 2007, 2012, 2015) is the practices 
constitutive of the “human” and “nonhuman”, 
these entities do not pre-exist the material-
discursive apparatuses through which they come 
into being (Fraser, 2002: 617). Indeed, who gets 
to count as human within human/nonhuman 
hybridizations is contingent on the specific 
apparatuses through which these entities are 
constructed. Barad understands scientifi c practice 
as performative, the objects and bodies under 
scientifi c investigation, their very ontology, is an 
eff ect of performative practice. However, agency, 
for Barad, is not a human prerogative, rather, she 
develops a performative account of materialisa-
tion that is open to intra-action with nonhuman 
entities, thereby paving the way for an analysis of 
embodiment that is indiscrete in matters of bodily 
contours and postanthropocentric in its consis-
tency. In this understanding of performativity, 
Barad (2007) emphasizes intra-action as opposed 
to interaction as there are no pre-existing 
entities to interact with one another. It is within 
phenomena that bodies and objects come to be, 
through the performative onto-epistemology of 
intra-action. As such, within scientifi c develop-
ment there are no pre-existing bodies, subjects 
and technologies for scientifi c knowledge-seeking 
practices to discover and describe, rather, it is 
through performative practices that these entities 
emerge, in intra-action with one another. As an 
important consequence, especially in light of an 
analysis of the fi eld of microbicide development, 
the boundaries between bodies, apparatuses of 
scientifi c development and technology evaporate: 
“...bodies are material-discursive phenomena that 
materialize in intra-action with (and, by defi nition, 
are indissociable from) the particular apparatuses 
of bodily production through which they come to 
matter (in both senses of the word)” (Barad, 2007: 
209). 
Within an onto-epistemology of agential 
realism (scientific) apparatuses have a central 
place. Because boundaries between the 
component entities of the phenomenon are 
determined through the apparatus, they do not 
pre-exist. Out of a context of indeterminacy, 
apparatuses construct the components of/within 
a phenomenon (such as for instance HIV, micro-
bicide and woman) by temporarily determining 
them as such. According to Barad (1998, 2007), 
an apparatus is not purely scientifi c, but a more 
complex and encompassing setup consisting 
of myriad systems of meaning and materialisa-
tion. Reading the RCT as an apparatus of bodily 
production allows me to ‘open the RCT up’ as not 
only a scientifi c space of facticity and objectivity 
(Epstein, 1996; Michael and Rosengarten, 2013; 
Latour, 1993; Will, 2007), but rather as a complex 
site where facts, ideals, bodies, virus, microbi-
cide candidates, sexual practices materialise and 
become meaningful in intimate, co-constitutive, 
relation - intra-action. Thus, to get ahead of my 
argument, reading the RCT as an apparatus of 
bodily production allows me to interrogate the 
fi eld’s ideals of empowerment and the eff ects of 
biomedical knowledge-seeking practices (here 
vaginal ulceration specifi cally) not as a mutually 
exclusive contradiction, but as an ambiguous 
relation constitutive of the woman/microbicide 
phenomenon on trial.
The story of Nonoxynol-9
Nonoxynol-9 based spermicides were the first 
agents to be considered for microbicide devel-
opment. Their testing commenced in the late 
1980s as spermicides that might protect against 
HIV (see Kreiss, 1992) even before the concept of 
a ‘microbicide’ was articulated. Nonoxynol-9 was 
understood to be a promising candidate by both 
the advocacy and biomedical fi eld because at the 
level of in vitro research Nonoxynol-9 showed to 
be potentially efficacious against several STDs 
and HIV. Furthermore, since Nonoxynol-9 based 
spermicides were already being manufactured, 
they were viewed as a potential microbicide that 
Science & Technology Studies 30(4)
53
would be relatively cheap and easy to produce 
(Roddy et al., 1998; Cook et al., 1998). Specifi cally, 
Nonoxynol-9 was a detergent that functioned 
by breaking down cell membranes. However, it 
raised concerns that it did not only break down 
cell membranes of the virus, but also of vagi-
nal skin and the cervix. Eventually, Nonoxynol-9 
based microbicides were shown to increase wom-
en’s susceptibility to HIV infection due to causing 
vaginal ulceration.
Nonoxynol-9 had been the active ingredient 
in spermicides since the 1950s and was approved 
for distribution before the FDA demanded 
any rigorous clinical trial testing. As a result, 
Nonoxynol-9 based spermicides were already 
available for use, but no one knew exactly how 
effi  cacious these spermicides were and, impor-
tantly, how safe they were. Advocates under-
stood the uncertainty of Nonoxynol-9’s safety 
and efficacy against STDs including HIV to be 
exasperated by public rumours that Nonoxynol-9 
would be eff ective against HIV infection. Conse-
quently, women and gay men were already 
using Nonoxynol-9 lubricated condoms for extra 
protection and Nonoxynol-9 sexual lubricants (in 
addition to its use as a spermicide). As a knock 
on effect, manufacturers put Nonoxynol-9 on 
condoms and in lubricants to tailor to the needs of 
those using Nonoxynol-9 based lubricants (Heise 
et al., 1998: 10). 
The context in which microbicides containing 
Nonoxynol-9 entered the human clinical trials 
during the late 1980s and were trialled for over 
10 years, was marked by a high variety of candi-
dates, trial designs and Nonoxynol-9 formula-
tions. Diff erent trial designs were used, not all 
of the trials were randomised controlled clinical 
trials, the amount of Nonoxynol-9 diff ered from 
compound to compound (as much as from 50 
mg to 1000 mg) and the suppositories diff ered, 
as some tested rings, some foams, some fi lms etc. 
(Martin et al., 1997; Van Damme et al., 2002; Forbes 
and Heise, 2000). Furthermore, the data produced 
by the safety trials as well as the effi  cacy trials 
was confl ictual and is still incredibly diffi  cult to 
compare. Some small scale observational studies 
reported promising results and called for more 
studies in large scale randomised controlled trials 
to validate their fi ndings (for instance Zekeng, 
1993). Other studies suggested the heightened 
risk increase of genital ulcers (for instance Niru-
thisard, 1991; Kreiss ,1992). Uncertainty within 
the scientifi c and advocacy fi eld emerged around 
these safety issues, the association with vaginal 
ulcers and, importantly, the association of 
vaginal ulcers and HIV infection. This uncertainty 
provoked a dedication in the fi eld for more and 
more research, despite Nonoxynol-9’s potential 
side-eff ects. 
The safety trials
The development of Nonoxynol-9 based microbi-
cide candidates had continuously been marked by 
a worrying safety profi le, in particular a concern 
for its association with vaginal ulcers, which could 
facilitate HIV virus in semen to enter a woman’s 
body. Consequently, the use of Nonoxynol-9 
based compounds would in fact increase women’s 
susceptibility to HIV infection instead of providing 
protection and inflict harm on the women par-
ticipating in the trials. A good example of this is 
the safety study of Niruthisard et al., published in 
1991. In a context of uncertainty about the safety 
of Nonoxynol-9, its possible future, rumours 
about its eff ect on the HIV virus and the fact that 
people were already using it as an HIV preven-
tative gel, this study sought to determine facts 
about Nonoxynol-9’s safety. The study was sup-
ported in part by Family Health International and 
the U.S. Agency for International Development, 
although (as the report states) the study does not 
necessarily refl ect FHI and AID policy (Niruthisard 
et al., 1991: 176). The Niruthisard safety study was 
a small scale observational study conducted on 
a small number of women at low risk of infection 
recruited from a family-planning clinic in Bangkok, 
Thailand. The women participants were asked to 
insert the compound once per hour, for four con-
secutive hours daily for a period of two weeks. 
This study showed that Nonoxynol-9 had harmful 
eff ects, as the report states:
Six of the women or 43% (...) had physical fi ndings 
that included disruption of the epithelium and/or 
bleeding. None of the women receiving placebo 
had abnormal physical fi ndings. The break in the 
epithelium on the cervical squamous epithelium 
of four women appeared to be the result of a 
thin layer of cells sloughing; in some cases the 
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layer of cells could be seen still partially attached. 
The epithelial sloughing appeared on the cervix 
in the area adjacent to the fornices and was not 
over the transformation zone. One woman had a 
severe reaction on the cervix that appeared similar 
to the strawberry cervix seen with trichomonas 
infection, but it was more severe and was bleeding 
and edematous. (...) One woman had physical 
fi ndings that included bleeding and sloughing 
of the vaginal mucosa, which also occurred in 
the fornices. All of the symptoms and fi ndings of 
the women resolved within 1 week of stopping 
N-9 use. None of the symptomatic reports were 
considered severe enough by the women to cause 
them to stop using the suppositories (Niruthisard, 
1991: 177).
The damage this statement describes appears to 
be severe, involving the skin lining women’s vagi-
nas and cervix shedding (sloughing) in certain 
places and bleeding. A ‘strawberry cervix’ refers 
to a cervix that is damaged as such that is has a 
punctuated appearance, making it look like the 
skin of a strawberry. This strawberry cervix was 
oedematous, meaning it was swollen with fl uid 
retention and shown to be bleeding. However, as 
the report articulates, none of these side-eff ects 
were considered severe enough by the women 
participants themselves to stop using the com-
pounds. This trial report raises questions about 
the particular local context within which such 
adverse events are experienced and given mean-
ing by women trial participants - experiences and 
meanings that might very well differ from bio-
medical protocol and bioethical considerations 
(Crane, 2010; Kingori, 2013). Why did the women in 
this study not think these side eff ects were severe 
enough? To what extent did the clinical trial con-
text itself impact on this articulation? Did the trial 
participants and scientists share the same under-
standing of what constituted a severe side eff ect? 
However, what the wider context of this consid-
eration was, is absent from the clinical trial report. 
It is not the woman within a wider context or her 
socio-economic situation, her sexual relation(s) 
and her body that is on trial here. Rather, this 
social, sexual and material context is reduced to 
only one fragment: the vagina/cervix and in par-
ticular Nonoxynol-9’s eff ects upon it.
 I argue that the clinical trial report is a powerful 
writing technology (Haraway, 1997: 26) that 
articulates the objective truth, here, of a scien-
tifi c object and the body on trial. This articulation 
enacts an agential cut that separates women’s 
vaginas from the body they are a part of, from 
the sexual relations in which they act and the 
economic currency they have (which becomes 
especially relevant in relation to the effi  cacy trials 
below). Barad (Barad, 2007: 148) writes that “appa-
ratuses are the material conditions of possibility 
and impossibility of mattering; they enact what 
matters and what is excluded from mattering”. 
In particular, an agential cut necessarily implies 
particular material-discursive exclusions that 
remain intimately related to the phenomenon 
produced by the apparatus, as what Barad has 
coined an exteriority-within – an eff ort to pay 
attention to the productive eff ects of exclusion 
inspired by Butler’s constitutive outside. As such, 
the particular agential cut under analysis here 
does not produce a mere objective truth about 
the eff ect on Nonoxynol-9 on the female body, 
here the vagina and cervix specifi cally. Rather this 
agential cut constructs and fragments women’s 
bodies within the story of Nonoxynol-9 as vaginas 
whose meaning is tied to their degree of ulcer-
ation, and in the same move excludes the wider 
social and material context through which these 
bodies emerge.
In contrast to the biomedical articulations of 
their investment in the development of vaginal 
microbicides, I argue that the scientifi c objectifi ca-
tion of Nonoxynol-9’s eff ect on the vagina/cervix 
does not merely construe facticity, but consti-
tutes a specifi c manner in which women’s bodies 
are made to matter in this particular biomedical 
enterprise. In other words, the entity of trial is not 
‘the female body’ assumed to pre-exist biomed-
ical knowledge seeking practices. Rather, this 
entity emerges through these practices, here, 
in an arguably problematic way. Furthermore, 
this entity emerges here as a human/nonhuman 
hybrid, a microbicide/woman relationality that 
brings to mind the feminist critiques on STS 
and in particular Actor Network Theory (ANT) 
spearheaded by Bruno Latour (see for instance 
1993, 2004) for its lack of engagement questions 
pertaining to the social and cultural processes 
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inherent to scientific practice through which 
‘the human’ is diff erentially constituted (see for 
instance, Star, 1991; Haraway, 1997; Van der Ploeg, 
2004; Braidotti, 2013). These feminist scholars 
critique STS and ANT for its focus on human/
nonhuman mingling, to the neglect on social 
and cultural processes through which the human 
comes to matter within human/nonhuman 
hybridisation. Indeed, the woman/microbicide 
entities at stake here are not hybrids to celebrate. 
What is particularly problematic is the fragmen-
tation through which the human is off ered up in 
relation to the microbicide candidate: the vagina/
cervix that is separated from the body that it is a 
part of, and the socio-materiality this body exists 
in, especially with regard to sexual relations and 
gender dynamics. The manner in which women’s 
bodies are made to matter here hinges on the 
exclusion of their wider socio-material relation-
ality. 
It is tempting to provide a reading of the devel-
opment of Nonoxynol-9 based microbicides as 
a critique against science, that foregrounds the 
manner in which women’s bodies are objectifi ed 
through biomedical endeavours and technolog-
ical development - a mode of critique character-
istic of the versatile fi eld of feminist science studies 
(Harding, 1986, 1991; Fox Keller and Longino 
1996[1982]; Martin, 1989, 1996) and which has a 
particularly rich history in the feminist critiques 
of reproduction science (for a generous overview 
see Thompson, 2005). Such a critique would also 
resonate with arguments against large scale 
outsourcing of drug trials and the profi t making 
machine of Big Pharma that Petryna (2009) 
engages in her writings on the exploitation of 
bodies for profi t. However, such a critique against 
science is also not able to fully articulate what 
is at stake here, as it would discard the feminist 
inhabitation of biomedicine that characterises 
the fi eld of microbicide development and thus 
the eff ort inherent in the testing of Nonoxynol-9. 
Furthermore, the development of vaginal micro-
bicides has a history of struggling for funding and 
has mostly been funded by the public sector and 
philanthropic organisations (Weber et al., 2005), 
thus as an enterprise it is not so much part of the 
exploitation of bodies for pharmaceutical profi t 
that Petryna describes. 
Within a context of high HIV prevalence, 
constrained access to healthcare and a wider socio-
economic environment that drives women’s risk 
of HIV infection, the development Nonoxynol-9 
based microbicides can be considered both 
ethical and unethical, politically desirable and 
problematic. This complexity resonates with the 
ethical and political ambiguity that Johanna Crane 
(2010) highlights in her critical reading of what 
constitutes ‘ethical science’ with regards to RCT 
testing of HIV treatment and prevention within 
resource poor settings. As she writes, “the debate 
is not merely about what is ‘right’ and ‘wrong’, but 
also about how science travels, and about how 
to forge useful and humane scientifi c knowledge 
across terrains of difference and inequality” 
(Crane, 2010: 861). What agential realism provides 
is an analytical framework in which this ambiguity 
(Montgomery, 2015) becomes visible, as apparent 
ethical and political contradictions do not rule one 
another out, but rather depend on one another in 
and for the woman/microbicide phenomenon.
The human effi  cacy trials
Between 1992 and 2002 three effi  cacy trials were 
conducted. These tested the effect of Nonox-
ynol-9 on women’s vaginal cells as well as its eff ect 
of dismantling the HIV virus. The fi rst was a study 
by Kreiss testing a vaginal sponge containing 
Nonoxynol-9. This trial was conducted amongst 
138 female sex workers in Nairobi, between Janu-
ary 1987 and June 1990 (Kreiss, 1992: 479). The trial 
showed a signifi cant increase in vaginal ulcers in 
the Nonoxynol-9 arm of the trial and was prema-
turely halted following the recommendations of 
the Data Safety and Monitoring Committee in July 
1990 (Kreiss, 1992: 479). The report continues to 
warn that 
[i]t is possible that prolonged and intensive 
exposure to nonoxynol 9 results in compromising 
the vaginal and vulvar epithelial integrity (...). 
Alternatively, nonoxynol 9 sponge use may directly 
cause genital ulceration as a result of chemical 
toxicity or mechanical irritation. Reactivation of 
genital herpes simplex virus infection is another 
possibility that was not excluded. These fi ndings 
are of particular concern because genital ulceration 
in women and men has been implicated as an 
important risk factor for HIV infection in both 
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American and African populations (Kreiss, 1992: 
481).
In 1998, the results of another effi  cacy trial were 
published, this time testing a vaginal fi lm contain-
ing Nonoxynol-9 on just over 1000 female sex 
workers in Cameroon (see Roddy et al., 1998). In 
line with the Kreiss study, this effi  cacy trial again 
showed an increase in vaginal ulceration. How-
ever, the trial did not show that vaginal ulcers in 
turn increased women’s susceptibility to HIV infec-
tion. Regardless of its fi ndings that the product 
increased vaginal ulceration the trial report ends 
with a call for more research (Roddy et al., 1998: 
509). Finally, in 2002, the Van Damme UNAIDS 
sponsored research on the vaginal gel COL-1492, 
also called Advantage-S, resulted in signifi cantly 
more women’s seroconversion in the active arm 
than in the placebo arm of the trial and associated 
Nonoxynol-9 with an increase in vaginal lesions 
and ulcers (although based on a safety trial that 
showed no harm (van Damme et al., 2002: 975)). 
In other words, this study showed that frequent 
use of Nonoxynol-9 based vaginal gel increased, 
rather than decreased, women’s vulnerability to 
HIV infection. 
This Phase III trial was conducted between 
September 1996 and June 2000. The popula-
tion included female sex workers in South Africa, 
Thailand, Benin and Côte d’Ivoire. Across the 
sites 892 sex workers were enrolled, 104 women 
became infected with HIV during the trial, 59 of 
whom in the Nonoxynol-9 arm. The higher prev-
alence of HIV infection in the product arm was 
possibly due to the vaginal ulcers and lesions 
most likely resulting from the use of Nonoxynol-9. 
The level of vaginal ulcers increased with the 
frequency of use. As the report states:
Our results show that nonoxynol-9 increased risk 
of HIV-1 infection compared with placebo. Risk 
was especially high in women who used the study 
drug gel more than 3.5 times per day and who 
also had a high incidence of lesions with epithelial 
disruption. This fi nding suggests that nonoxynol-9 
has an adverse eff ect on vaginal integrity when 
used frequently, thus increasing women’s 
susceptibility to HIV-1 infection. At low frequency 
use, nonoxynol-9 had no eff ect, either positive or 
negative, on HIV-1 infection (van Damme, 2002: 
975).
After the Van Damme trial showed a higher 
amount of HIV infections in the Nonoxynol-9 
arm of the trial, the World Health Organization 
released a statement in 2002 that Nonoxynol-9 is 
ineff ective against HIV and might increase wom-
en’s vulnerability to HIV infection. “Spermicides 
containing nonoxynol-9 do not protect against 
HIV infection and may even increase the risk of 
HIV infection in women using these products fre-
quently” (WHO, 2002, 1). This statement marked 
the end of the development of Nonoxynol-9 
based microbicides after over 10 years of testing.
It is important to note that the Van Damme trial 
also showed that women’s vulnerability to HIV 
infection increased with sexual activity and that 
Nonoxynol-9’s eff ect was therefore related to how 
women used the microbicide candidate. After the 
Van Damme trial fi nished, a social research study 
was conducted that supports this suggestion. This 
research was conducted at one of the sites of the 
Van Damme trial, amongst a group of HIV negative 
sex workers who worked at truck stops in Durban, 
South Africa. The primary aim of this study was to 
show the manner in which these women under-
stood the gel’s (placebo or Nonoxynol-9) eff ective-
ness. This research articulates women’s belief and 
hope that they were using the Nonoxynol-9 gel 
instead of placebo and that the gel was eff ective, 
regardless of understanding the RCT’s aims and 
protocol. The study explains:
The gel took on added signifi cance as a protective 
device in light of the fact that many women 
reported that some of their clients and partners 
did not want to use condoms. Some women were 
concerned about the condom’s eff ectiveness and 
viewed the gel as providing better protection. 
Others believed that in the case of condom 
breakage, the gel would protect them: “Even if [the 
condom] bursts, we don’t have any problems. We 
have our protector.”
At trial baseline, only 17% of the women reported 
that they were protected by condoms in more than 
50% of the sex acts they engaged in. One woman 
told her clients who refused to use condoms that 
she was using the gel; she indicated that these men 
felt protected by the gel.
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Belief in the gel’s effi  cacy was further reinforced by 
the economic pressures on the women and their 
concerns about losing clients:
“You try to force a person to use a condom but 
when you see this person really doesn’t want to use 
it and is going to the next person who will sleep 
with him without a condom, and the money he has 
a lot, you just think that you have your gel, and you 
take the money” (Mantell et al., 2006: 1075).
The differences between the manner in which 
these women articulated their use of Nonoxynol-9 
as ‘their protector’ is in striking contrast to the 
clinical trial report of the aforementioned safety 
study, the Van Damme trial report and the WHO 
statement. The use of Nonoxynol-9 is embedded 
within women’s vulnerability to HIV infection, 
their specifi c sex work economies and the hope 
they have for an eff ective tool to protect them-
selves, where the power to demand condom use 
is scarce. The candidate as a nonhuman ‘protec-
tor’ articulates a specifi c scenario in which women 
participants struggled to negotiate condom use, 
namely the specifi c power relations between sex 
worker and client which put these women at risk 
of HIV infection. Moreover, it is exactly this use 
of Nonoxynol-9 without a condom that would 
further the extent to which trialists are able to 
show the candidates effi  cacy, as this is based on 
women’s HIV infections. The women participants’ 
use of a microbicide candidate in a context where 
they are unable to negotiate condom use and 
are as such vulnerable to HIV infection is antici-
pated in the trial’s design and the central place it 
aff ords to statistically signifi cant sero-conversions. 
Furthermore, taking into account a history of 
struggling for funding, women trial participants’ 
vulnerability to HIV infection also makes the trial-
ing of microbicides more aff ordable and thus real-
izable. In other words, this Nonoxynol-9 candidate 
as women’s protector and as an (in)efficacious 
compound were mutually constitutive. But this 
specifi c woman/microbicide hybrid as a human/
nonhuman relation is vastly removed from the 
fi eld’s promise of empowerment. 
Women’s vulnerability to HIV infection in the 
Van Damme trial is compounded by the bio-
ethical decision that the women who serocon-
verted in the Van Damme Advantage-S trial, 
possibly due to the use of Nonoxynol-9 and the 
resulting vaginal lesions and ulcers, were not 
given access to anti-retroviral (ARV) treatment. 
At the time, ARV treatment was not available in 
the countries participating in the study. Making 
this treatment available for the women in the trial 
would therefore, in line with bioethical standards 
of care, be coercive (Van Damme et al., 2002: 976). 
In other words, making treatment accessible for 
the women who were infected with HIV possibly 
due to Nonoxynol-9 induced ulcers was consid-
ered unethical according to the bioethical logic 
of the time. In the clinical trials after Nonoxynol-9 
as ARV treatment slowly became more accessible 
globally, to some extent, this ethical standard 
has been changed and women in the trials now 
do have access to ARVs when they serocon-
vert (UNAIDS and WHO., 2000; Heise et al., 2008; 
McGrory et al., 2010). However, the Nonoxynol-9 
trials do raise major ethical and political questions 
regarding the role of women trial participants and 
their specifi c vulnerability to HIV infection. 
The advocacy response
After the van Damme trial, the GCM made an 
eff ort to explain the complexity of the trial results 
and focused on the removal of Nonoxynol-9 lubri-
cated condoms and sexual lubricants. The GCM 
did not publicly engage with the protocol that 
failed to provide ARVs to the women who sero-
converted in the trial. Rather, the GCM’s point of 
focus was the extent to which the trial was harm-
ful to women. As such, Heise and Forbes (2000) 
published an article in Reproductive Health Mat-
ters entitled What’s Up With Nonoxynol-9? and the 
GCM website devoted a page to Nonoxynol-9 in 
which they disseminated information. Both the 
GCM website and the article by Heise and Forbes 
(2000) situate the difficulty of the trial results 
within a larger HIV epidemic. Specifically, they 
make a statement that the RCT in itself does not 
increase women’s risk: 
It should be noted, however, that the incidence 
of new HIV infections in both study groups was 
lower than that seen in the wider population of sex 
workers from whom the women were recruited. 
This contradicts the fear expressed by some AIDS 
activists that participation in microbicide trials may 
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in itself, increase women’s HIV risk. The challenges 
associated with designing ethical prevention 
trials are complex, given the fact that some sero-
conversion among participants is likely to occur 
despite condom promotion and other safeguards. 
But they are not insoluble (GCM, 2010c; Forbes and 
Heise, 2000).
The extent to which the RCTs increase women’s 
vulnerability to HIV infection, was the GCM’s pri-
mary engagement with the biomedical fi eld (see 
for instance GCM, 2007b). However, the statement 
above shows that the GCM’s ethical deliberations 
did not focus on the biomedical process of test-
ing microbicide candidates through the RCT or, 
specifi cally, the set of relations this type of testing 
invites, such as the need for women’s HIV infec-
tion, the specifi cities of women’s high risk behav-
ior and the role that the microbicide candidate 
necessarily plays (and in part is anticipated to play) 
herein. Thus, the role that women’s vulnerability 
to HIV infection plays in the clinical trial is not 
placed under scrutiny, and with this the constitu-
tive power of biomedical trialling practices is not 
placed under interrogation.
The women participating in the trials are sought 
out on a global scale because of their vulnerability 
to HIV infection which, as advocates tell us, is 
understood as related to their lack of resources 
and diminishment of power that renders them 
vulnerable to HIV infection. Despite its preventa-
tive (empowering) measures, the trial depends 
on this vulnerability for its scientifi c validity and 
anticipates this vulnerability in the central role 
it aff ords to statistically signifi cant sero-conver-
sion. Although the advocacy aim was to create 
a feminist science, where the trial would be a 
site of empowerment, the GCMs response to the 
Nonoxynol-9 trials, their comparison between the 
inside and the outside of the trial, maintains the 
trial as a scientifi c space cut off  from processes of 
power. Thereby they reiterate the ‘gold standard-
ness’ of the RCT and facilitate the exclusion of the 
GCM’s own social concerns from the RCTs they 
conducted. Consequently, the ethical and political 
ambiguity between ideals of empowerment 
and biomedical knowledge-seeking practices, 
intrinsic to microbicide testing, is not addressed. 
As Mike Michael and Marsha Rosengarten (2012: 
40) write, “the RCT entails its own necessity, as it 
were – not least because of the exclusion of the 
very conditions that give rise, for instance, to 
infections”. I suggest that the ability to question 
the extent to which biomedical process is consti-
tutive of women’s vulnerability to HIV within the 
trials is of vital importance to be able to engage 
the full ethical complexity inherent to the testing 
of vaginal microbicides through a biomedical 
process that centralises women’s HIV infections 
and anticipates women’s inability to protect them-
selves from HIV.
Of course, the field has had awareness of 
the ethical controversies of the trials, but the 
biomedical process inherent to the clinical trials 
and its specifi c practices through which the facts 
emerge is not seen as part of what makes these 
RCTs potentially controversial. The materiality of 
the female body and the effi  cacy of the microbi-
cide to prevent the HIV virus from entering this 
body is understood as the only materiality at stake 
in the development of microbicides. Further-
more, biomedical knowledge seeking practices 
are understood as the only manner in which to 
gain access to this materiality. An agential realist 
conception of the RCT as an apparatus of bodily 
production, a socio-scientific milieu through 
which bodies come to matter, neither under-
stands biomedical matter to be the only materi-
ality at stake, nor does it gives sole authority to 
biomedicine to determine and describe this mate-
riality. Rather, agential realism enables an analysis 
of the multiplicity of materialities enacted in and 
through the clinical trials, pertinent for an ethical 
and political assessment of how women’s bodies 
come to matter in the trials, including their socio-
sexual risk of HIV infection and in accordance to 
feminist ideals.
Concluding remarks: 
multiple materialities
In this paper, I have argued that agential realism 
is able to provide a robust analytical framework 
to interrogate the political and ethical eff ects of 
this ambiguity that the fi eld’s own discourse of 
empowerment does not sufficiently provide. In 
particular, it shows the need to take social sci-
ence research seriously within the trialling of 
vaginal microbicides (and HIV prevention in a 
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more encompassing sense) instead of being 
either a secondary exercise or an afterthought, 
for instance in case of the Van Damme trial. Times 
have changed since the Nonoxynol-9 trials and 
microbicide clinical trials now often include a 
social research arm, which I indeed understand 
to be imperative. However, if we do not come to a 
multiple understanding of materiality, where bio-
medical knowledge-seeking practices and social 
science are understood to be of equal value and 
authority to determine what matters in the devel-
opment of microbicides (and HIV prevention tech-
nologies more broadly defined), social science 
analyses run the risk of remaining secondary, or 
indeed complicit. Consequently, the power mech-
anisms in play within and through the RCT will 
remain obscured in such a hierarchy of value. This 
is what I understand to be one of the crucial con-
tributions STS is able to make within the fi eld of 
global health - it elucidates the constitutive power 
of science and technology and thereby engages 
the politics and ethics of how bodies come to 
matter under the rubric of ‘global health’.
In the beginning of this paper, I asked: what 
happens to feminist ideals of empowerment when 
they materialise through biomedical practice? The 
concept of empowerment has functioned as a 
vehicle of entry for women’s specifi c vulnerability 
and receptivity to the HIV virus to play a major role 
in HIV global health discourse. It has functioned, 
and still functions, as a driving force behind the 
development of vaginal microbicides. It has 
brought women’s health advocacy and biomedi-
cine in productive relation with each other. 
The promise of vaginal microbicides is indeed 
a promise that entangles the biological vulner-
ability of the female body to HIV and women’s 
social risk of infection – a particular medicalisation 
of powerlessness and its promised transforma-
tion through the scientifi c development of a tech-
nology that is envisioned to transform the body 
and sexual power relations. However, this feminist 
inhabitation of science and the aim to materialise 
a feminist ideal through biomedical process is 
where an intrinsic ambiguity emerges between 
the promise of empowerment and the eff ects of 
a biomedical search for facticity through clinical 
trial testing – here women’s HIV infections within 
the RCTs and vaginal ulceration specifi cally. 
But how does this feminist ideal of empower-
ment stand in relation to neomaterialist feminist 
work? Empowerment as a concept emerging out 
of the second wave feminisms of the 1960s and 
1970s stands in awkward relation to neomateri-
alist theory (although I appreciate Rosi Braidot-
ti’s (2011b) unapologetic use of the concept), in 
particular with regards to underlying understand-
ings of power as predominantly a social force - 
gender (although there are of course exceptions 
to such understandings of power as second wave 
feminism is not a singular fi eld, see Van der Zaag, 
forthcoming). I do not wish to end this paper with 
a call towards empowerment, or an argument 
that hinges on a ‘return’ to such discourses and 
ideals, but I do argue that there is purchase for 
paying serious attention to the politics of mate-
riality and the various exclusions that might be 
enacted if we fail to do so. Although feminist 
neomaterialisms encompass a rich multifarious 
posthuman landscape, increasingly the breach 
of nature/culture dichotomies have come to 
stand in for feminist analysis, a certain immanent 
politics that runs the risk of neglecting attention 
to specifi c problems pertaining to sex(uality) and 
gender (Squier and Littlefi eld, 2004; Hinton and 
Van der Tuin, 2014), including matters of post-
colonialism and race (Willey, 2016; Leong, 2016). 
Such an understanding has direct impact on 
which problems are understood to be signifi cant 
for analysis and the discourses available to articu-
late such an analysis. If what is at stake in feminist 
neomaterialisms is only understood as biomatter, 
i.e. systems of meaning prevalent in the natural 
sciences, materialities of sex(uality) as a lived and 
gendered project of survival (Bell, 2008) as those 
foregrounded by Judith Butler (1990, 1993) run 
the risk of being neglected if not fully excluded. 
This exclusion, I argue, is problematic in terms of 
feminist theory as a political project. 
In particular relation to STS and its predominant 
focus on the celebration of human/nonhuman 
hybridity, Nonoxynol-9 shows that a celebration of 
human/nonhuman mingling does not substitute a 
political analysis. The human/nonhuman relations 
in the story of Nonoxynol-9 do not only matter 
as biomateriality, but also within the articulated 
lived experiences of women in the HIV epidemic 
- biomedical bodies are not the only materialities 
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at stake. What the story of Nonoxynol-9 shows 
is the importance of a feminist neomaterialism 
that is focused not merely on Science as the privi-
leged zone of materiality, but on multiple mate-
rialities: the materiality of lived reality, sex work 
economies, HIV infection, (in)effi  cacious micro-
bicide candidates, the vulnerability of bodies, 
vaginal ulceration and the potential materiality of 
a diff erent future less tainted by HIV. Such a focus 
on multiplicity is indeed a ‘politics of materiality’, 
and ethics, I would add, that invites a pertinent 
critical self-reflection regarding the worlds we 
bring into being and those we exclude from 
mattering as feminist theorists located in the 
scenes of STS. 
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NOTES
1 A thorough discussion of these theoretical debates is beyond the scope of this paper, for a more elaborate 
discussion see Van der Zaag forthcoming.
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